Literature DB >> 16556442

Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model.

Keiichi Ashikaga1, Takao Kobayashi, Masaomi Kimura, Shingen Owada, Shingo Sasaki, Atsushi Iwasa, Ken-ichi Furukawa, Shigeru Motomura, Ken Okumura.   

Abstract

Structural in addition to electrical remodeling may be induced by persistent atrial fibrillation per se and make atrial fibrillation refractory to antiarrhythmic drug therapy. Matrix metalloproteinases (MMPs) contribute to structural remodeling in the interstitial space. Amiodarone is effective in treating persistent atrial fibrillation compared with other antiarrhythmic drugs. In mongrel dogs, right atrial pacing at 540 beats/min (bpm) was performed along with ventricular pacing at 100 bpm for 6 weeks after atrioventricular node ablation. Right atrial pacing at 400 bpm was continued for 4 weeks with (n=5) or without (n=5) oral amiodarone (30 mg/kg/day). In sham dogs, only ventricular pacing was done with (n=4) or without (n=6) amiodarone. In atrial pacing without amiodarone group, electrical remodeling characterized by monophasic action potential duration shortening, loss of action potential duration-rate adaptation and depressed conduction velocity and structural remodeling characterized by slightly but significantly increased interstitial fibrosis and enhanced MMP-2 activity compared with sham group were observed, and sustained atrial fibrillation was easily induced. In atrial pacing with amiodarone group, both electrical and structural remodeling were reversed and sustained atrial fibrillation was not induced. In sham group with amiodarone, action potential duration prolongation and depressed conduction velocity compared with sham without amiodarone were observed, but either increased fibrosis or enhanced MMP-2 activity was not observed. Not only electrical but structural remodeling were induced in a canine persistent atrial fibrillation model. Amiodarone reversed both of them, which may be related to its high efficacy in preventing recurrence of persistent atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556442     DOI: 10.1016/j.ejphar.2006.02.023

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

2.  Pleiotropic actions of amiodarone: still puzzling after half a century.

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-09       Impact factor: 3.000

3.  Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Future Cardiol       Date:  2011-11

4.  Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.

Authors:  Kazunori Uemura; Masashi Inagaki; Can Zheng; Toru Kawada; Meihua Li; Masafumi Fukumitsu; Masaru Sugimachi
Journal:  Heart Vessels       Date:  2016-11-14       Impact factor: 2.037

Review 5.  Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.

Authors:  Rajeev Pathak; Dennis H Lau; Rajiv Mahajan; Prashanthan Sanders
Journal:  J Atr Fibrillation       Date:  2013-12-31

Review 6.  Connexin Remodeling Contributes to Atrial Fibrillation.

Authors:  Michelle M Jennings; J Kevin Donahue
Journal:  J Atr Fibrillation       Date:  2013-08-31

7.  Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy.

Authors:  Attila Benák; M Kohári; A Herczeg; A Makai; G Bencsik; L Sághy; R Pap
Journal:  J Interv Card Electrophysiol       Date:  2019-02-28       Impact factor: 1.900

8.  Does the expression of transforming growth factor β-1: affect the outcome of the radiofrequency modified maze procedure in patients with rheumatic atrial fibrillation?

Authors:  Wei Wang; Lei Liu; Yuan Li; Sheng-Shou Hu; Yun-Hu Song; Xin Wang
Journal:  Tex Heart Inst J       Date:  2012

9.  Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; José M Di Diego; Serge Sicouri; Marcela Ferreiro; Leif Carlsson; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-09-16       Impact factor: 6.343

10.  Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity.

Authors:  L Kang; M Q Zheng; M Morishima; Y Wang; T Kaku; K Ono
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.